---
title: "Cholesterol and Lipid Profile on Steroid Cycle"
description: "HDL/LDL impact on cycle, especially from orals: how to manage with omega-3, cardio and compound selection."
lang: en
dateModified: 2026-05-23
canonical: https://anaprotokol.com/en/guides/cholesterol-on-cycle
---

# Cholesterol and Lipid Profile on Steroid Cycle

The **impact of steroids on the lipid profile** is one of the most documented and most underestimated effects: felt at zero, visible on every blood panel. The medium- to long-term consequence is cardiovascular — and it is the single biggest item on the risk side of a multi-year cycling career, far more than the more visible fears (gyno, acne).

This guide explains how steroids — and especially **17-alpha-alkylated orals** — wreck the lipid profile, which values to watch, and which levers actually buffer the impact. It belongs to the [blood work on cycle](/en/guides/blood-work-on-cycle) cluster.

## Why steroids wreck the lipid profile

Anabolic steroids increase hepatic lipase activity, the enzyme that breaks down HDL cholesterol (the 'good' cholesterol — the one that ferries excess cholesterol back to the liver). Result: HDL drops, sometimes drastically. In parallel, several compounds raise LDL (the 'bad' cholesterol). The LDL/HDL ratio, one of the best predictors of atherosclerotic cardiovascular risk, deteriorates in both directions at once [2].

The effect is much more pronounced under **17-alpha-alkylated orals** ([Winstrol](/en/molecule/winstrol), [Anavar](/en/molecule/anavar), [Anadrol](/en/molecule/anadrol), [Dianabol](/en/molecule/dianabol)) because of their first-pass hepatic metabolism. Winstrol has a particularly bad reputation for HDL: drops of 50 to 70% in a few weeks are regularly reported in clinical practice for oral users [3].

## Markers and their targets

| Marker | Adult male target | Reading on cycle |
| --- | --- | --- |
| HDL | > 40 mg/dL (1.0 mmol/L) | Expected drop; under 30 mg/dL: alert |
| LDL | < 130 mg/dL (3.4 mmol/L) | Frequent rise, especially under orals |
| Total cholesterol | < 200 mg/dL (5.2 mmol/L) | Possible rise |
| Triglycerides | < 150 mg/dL (1.7 mmol/L) | Variable; possible drop under testosterone |
| Apolipoprotein B (apoB) | < 90 mg/dL | Marker of atherogenic particle count |
| Lp(a) | < 30 mg/dL | Genetic risk marker, measure once |

### HDL: the most sensitive marker

If a single lipid marker has to be tracked rigorously on cycle, it is HDL: it drops the fastest and the deepest. A normal value (> 40 mg/dL in men) that falls toward 20 mg/dL in a few weeks under an oral is a major signal. Recovery after stopping the oral is usually partial in the following weeks and complete over a few months, but repeated protocols leave a cumulative footprint [1].

> Standard LDL sometimes underestimates the real risk: for users on orals or long cycles, **apolipoprotein B (apoB)** is a more precise marker of circulating atherogenic particle count. It is starting to enter sharper cardiovascular monitoring practice, worth requesting on top of the standard lipid panel where possible.

## The compounds that wreck lipids most

- **Stanozolol (Winstrol).** Worst reputation on HDL — see the [Winstrol](/en/molecule/winstrol) page.
- **Oxandrolone (Anavar).** Often labeled 'tolerable', it still clearly degrades the lipid profile. See [Anavar](/en/molecule/anavar).
- **Oxymetholone (Anadrol).** One of the most marked lipid impacts, on top of its hepatotoxicity.
- **Methandrostenolone (Dianabol).** Clear LDL rise and HDL drop.
- **Trenbolone.** Heavy overall cardiovascular impact — HDL crash among the consequences.

### Compounds relatively 'softer' on lipids

On the injectable side, testosterone-only at a contained dose ([enanthate](/en/molecule/test-enanthate) for example) has a more modest lipid impact than orals. Nandrolone and boldenone are also less aggressive on HDL than 17α-alkylated orals. That does not erase the effect, but it cuts it substantially [3] — one of the arguments in favor of 'all-injectable' cycles for users who want to limit their lipid footprint.

## The management levers

### 1. Compound selection and duration

The first lever — and the most effective — sits upstream: limit orals (duration and stacking), favor injectables as the base, cap oral windows at 4 to 6 weeks max, and do not stack two 17α-alkylated orals. For anyone systematically pairing Anadrol + Dianabol or Winstrol + Anavar, the lipid profile is going to wreck itself, and omega-3 will not change much.

### 2. Omega-3

Omega-3 fatty acids (EPA + DHA) at a substantial dose — typically 2 to 4 g per day of combined EPA+DHA, from a quality source — are the most consistently cited supplement for buffering the lipid impact. The effect is real but partial: they are not enough to neutralize the impact of stacked orals at full dose [4].

### 3. Cardio

Regular cardiovascular activity (zone 2 for 150 to 200 min/week, plus a few harder sessions) raises HDL, lowers triglycerides and blood pressure, and improves endothelial health. It is one of the variables that, over the long run, separates cyclers who stay cardiovascularly healthy from those who drift.

### 4. Nutrition

- Keep a meaningful share of the diet on whole, unprocessed foods (vegetables, fruit, legumes, fatty fish).
- Limit very high saturated fat intake combined with orals.
- Moderate alcohol: it stacks on top of hepatic load from orals and worsens the lipid profile.

### 5. Statins: not self-prescribed

Some advanced users take statins (atorvastatin, rosuvastatin) on prescription to buffer the impact of cycles heavy in orals or prolonged blasts. This is a medical decision, not a DIY: statins have their own side effects (muscular, hepatic) that can stack with those of orals. Do not take them without a prescription.

> No supplement fully neutralizes the lipid impact of steroids — orals especially. The most effective way to protect your lipid profile is to limit and dose orals carefully. Cumulative cardiovascular risk over years is the main argument for moderation in this practice.

## When and how to monitor your lipid profile

- **Baseline** 2 to 4 weeks before the first injection: full lipid panel, ideally with apoB.
- **Mid-cycle** (week 4 to 8 depending on cycle length), especially if an oral is in play: lipid panel check. If the oral is capped at 4 to 6 weeks, take the draw in the last week of the oral.
- **Post-PCT**: lipid recovery panel 6 to 8 weeks after the complete stop of all compounds.

The lipid panel is drawn fasted (10 to 12 hours without calories, water OK) for triglyceride reliability in particular. AnaProtoKol's [blood work feature](/register) imports the lab PDFs and plots each marker on its own curve, with the baseline as reference — the format that lets you read the trajectory and not just the point. For the global schedule, see [blood test schedule for a cycle](/en/guides/blood-test-schedule-cycle).

## FAQ

### How long does HDL take to recover after a cycle of orals?

HDL recovery after stopping 17α-alkylated orals is generally gradual over several weeks to a few months. A meaningful part returns in the 4 to 8 weeks after stopping, but the return to baseline values can take longer, especially after long or repeated cycles. Repeated protocols often leave a cumulative footprint: a user after several years of cycles can have a less favorable lipid baseline than at the start of their career.

### Omega-3: which form and what dose?

Favor a quality source (fish oil in triglyceride or rTG form, or algae oil for vegetarians) with the EPA and DHA dose clearly stated — not just 'total omega-3'. The dose commonly cited in the cycling context is 2 to 4 g of combined EPA+DHA per day, taken with a meal. Cheap supplements of unclear quality will not deliver: it is the actual EPA+DHA total that matters, and quality (peroxides, contaminants) drives GI tolerance. Brands like Nordic Naturals, Carlson and Now's Ultra Omega-3 are commonly cited in the community.

### Should I get a coronary calcium score on long cycles?

For users on cumulative cycles over years (blast and cruise, multi-year cycling career), the coronary calcium score is a non-invasive exam (low-dose CT) that measures calcified atheroma in the coronary arteries. It gives a direct picture of long-term cardiovascular drift — far more tangible than a lipid panel. Its relevance is discussed with a cardiologist typically from the fifth decade onward, or earlier if the lipid profile is heavily degraded. Not a routine cycle exam, but a useful tool in certain cycling paths.